Pfizer Inc. v. Watson Pharmaceuticals Inc.
1:10-cv-00357
Overview
Parties
Defendant
Counter Claimant
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 16 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 5,100,899 A Asserted | US Continuation / Sibling | View Official Patent → |
| 🇪🇺 European Patent Office (UPC States) | EP 90,110,612 A | European Counterpart (EP) | View Official Patent → |
| 🇪🇺 European Patent Office (UPC States) | EP 401,747 B1 | European Counterpart (EP) | View Official Patent → |
| 🇨🇦 Canada | CA 002018287 A | Canada Counterpart | View Official Patent → |
| 🇨🇦 Canada | CA 2018287 C | Canada Counterpart | View Official Patent → |
| 🇩🇪 Germany | DE 2001199045 | Germany Counterpart | View Official Patent → |
| 🇩🇪 Germany | DE 10199045 I2 | Germany Counterpart | View Official Patent → |
| 🇩🇪 Germany | DE 69025803 T | Germany Counterpart | View Official Patent → |
| 🇰🇷 South Korea | KR 1019900008 | South Korea Counterpart | View Official Patent → |
| 🇰🇷 South Korea | KR 0160957 B1 | South Korea Counterpart | View Official Patent → |
| 🇯🇵 Japan | JP 2146408 A | Japan Counterpart | View Official Patent → |
| 🇯🇵 Japan | JP 2969150 B2 | Japan Counterpart | View Official Patent → |
| 🇺🇸 United States | US 5,212,155 A | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 5,308,847 A | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 5,403,833 A | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5100899
Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
|
Filed: 1989-06-06
Issued: 1992-03-31
|
Expired (Term Ended)
+1492d PTA
Expires: 2013-07-07
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
High PTA (+1492 days) / Cellect Scrutiny — Over 1492 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
9
Dispositive
0
Granted
0
Denied
0
Pending / Review
9
Motions by Category
Key Dispositive Motions & Rulings